Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

James W Denham; David Joseph; David S Lamb; Nigel A Spry; Gillian Duchesne; John Matthews; Chris Atkinson; Keen-Hun Tai; David Christie; Lizbeth Kenny; Sandra Turner; Nirdosh Kumar Gogna; Terry Diamond; Brett Delahunt; Christopher Oldmeadow; John Attia; Allison Steigler

Journal article

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

James W Denham, David Joseph, David S Lamb, Nigel A Spry, Gillian Duchesne, John Matthews, Chris Atkinson, Keen-Hun Tai, David Christie, Lizbeth Kenny, Sandra Turner, Nirdosh Kumar Gogna, Terry Diamond, Brett Delahunt, Christopher Oldmeadow, John Attia, Allison Steigler

The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2014

DOI: 10.1016/S1470-2045(14)70328-6

University of Melbourne Researchers

Gill Duchesne Author The Sir Peter MacCallum Department of Oncology

Keen-Hun Tai Author Clinical Pathology

Grants

Funding Acknowledgements

National Health and Medical Research Council of Australia, Novartis Pharmaceuticals Australia, Abbott Pharmaceuticals Australia, New Zealand Health Research Council, New Zealand Cancer Society, University of Newcastle (Australia), Calvary Health Care (Calvary Mater Newcastle Radiation Oncology Fund), Hunter Medical Research Institute, Maitland Cancer Appeal, Cancer Standards Institute New Zealand.